The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

James L. Abbruzzese, Ralf Grunewald, Elizabeth A. Weeks et al. · Journal of Clinical Oncology · 1991 · 759 citations

Medicine, Oncology, Pharmacology +13

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

Larry W. Hertel, G B Boder, Julian S. Kroin et al. · PubMed · 1990 · 683 citations

Medicine, Oncology, Pharmacology +11

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

Volker Heinemann, Larry W. Hertel, Gerald B. Grindey et al. · PubMed · 1988 · 509 citations

Medicine, Pharmacokinetics, Pharmacology +13

Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

Ralf Grunewald, James L. Abbruzzese, Peter G. Tarassoff et al. · Cancer Chemotherapy and Pharmacology · 1991 · 250 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +4

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.

Ralf Grunewald, Hagop M. Kantarjian, Meiqing Du et al. · Journal of Clinical Oncology · 1992 · 218 citations

Medicine, Pharmacokinetics, Pharmacology +17